Cizzle Biotechnology Holdings PLC (GB:CIZ)
LSE:CIZ
Want to see GB:CIZ full AI Analyst Report?
CIZ Stock Chart & Stats
1.55 p
<0.01 p(0.26%)
At close: 4:00 PM EST
1.55 p
<0.01 p(0.26%)
Day’s Range― - ―
52-Week Range1.20 p - 3.90 p
Previous CloseN/A
Volume291.66K
Average Volume (3M)1.23M
Market Cap
£12.96M
Enterprise Value12.42M
Total Cash (Recent Filing)£116.00K
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta-0.45
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding424,963,200
10 Day Avg. Volume655,017
30 Day Avg. Volume1,232,506
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)-18.07
Price to Sales (P/S)0.00
P/FCF Ratio-12.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Diagnostics StrategyCizzle’s clear strategic focus on blood-based early lung cancer diagnostics targets a durable, high-value clinical need. If clinical validation succeeds, the business model supports recurring demand from screening and diagnostic workflows and a differentiated product franchise with long-term commercial potential.
Low Reported Financial LeverageReported minimal debt reduces immediate solvency and interest-rate risks, giving management flexibility in financing clinical programs. For a pre-revenue biotech, low leverage preserves optionality to pursue non-debt funding (equity, grants, partnerships), supporting runway decisions over the medium term.
Cash-flow Accounting TransparencyFree cash flow tracking near net income indicates losses reflect real cash outflows rather than large non-cash items. That transparency improves runway forecasting and fundraising sizing, aiding management and investors in planning clinical spend and capital needs with fewer surprises.
Bears Say
Pre-revenue With Persistent LossesCizzle remains pre-commercial with consistent negative EBIT and net losses across years, so core commercial economics are unproven. Continued operating cash burn without product sales heightens execution and financing risk, making progress dependent on successful trials and capital raises.
Eroded / Negative Shareholders' EquityEquity erosion to a negative balance is a structural red flag that limits financial flexibility. Negative equity can restrict access to institutional financing, complicate partnerships and licensing discussions, and increases insolvency risk if losses persist or fresh capital is delayed.
Shrinking Asset Base And Funding DependenceA sharp drop in total assets reflects a shrinking capital base and reduces internal capacity to fund trials and validation. This structural decline increases reliance on external funding, raising the probability of dilution, program delays, or downscoping if new capital is not secured in the next several quarters.
Cizzle Biotechnology Holdings PLC News
CIZ FAQ
What was Cizzle Biotechnology Holdings PLC’s price range in the past 12 months?
Cizzle Biotechnology Holdings PLC lowest share price was 1.20 p and its highest was 3.90 p in the past 12 months.
What is Cizzle Biotechnology Holdings PLC’s market cap?
Cizzle Biotechnology Holdings PLC’s market cap is £12.96M.
When is Cizzle Biotechnology Holdings PLC’s upcoming earnings report date?
Cizzle Biotechnology Holdings PLC’s upcoming earnings report date is Sep 24, 2026 which is in 107 days.
How were Cizzle Biotechnology Holdings PLC’s earnings last quarter?
Cizzle Biotechnology Holdings PLC released its earnings results on Apr 30, 2026. The company reported -0.001 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.001 p.
Is Cizzle Biotechnology Holdings PLC overvalued?
According to Wall Street analysts Cizzle Biotechnology Holdings PLC’s price is currently Overvalued.
Does Cizzle Biotechnology Holdings PLC pay dividends?
Cizzle Biotechnology Holdings PLC does not currently pay dividends.
What is Cizzle Biotechnology Holdings PLC’s EPS estimate?
Cizzle Biotechnology Holdings PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cizzle Biotechnology Holdings PLC have?
Cizzle Biotechnology Holdings PLC has 424,963,200 shares outstanding.
What happened to Cizzle Biotechnology Holdings PLC’s price movement after its last earnings report?
Cizzle Biotechnology Holdings PLC reported an EPS of -0.001 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.636%.
Which hedge fund is a major shareholder of Cizzle Biotechnology Holdings PLC?
Currently, no hedge funds are holding shares in GB:CIZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cizzle Biotechnology Holdings PLC
Cizzle Biotechnology Holdings Plc specializes in developing an advanced immunoassay diagnostic test. This innovative tool aims to identify the CIZ1B biomarker, facilitating the early detection of lung cancer. The company, previously known as Cizzle Biotechnology Limited, officially changed its corporate identity to Cizzle Biotechnology Holdings Plc in May 2021. Its main operational base is situated in London, United Kingdom.